Larotaxel (Synonyms: XRP9881) |
Katalog-Nr.GC36424 |
Larotaxel (XRP9881) ist ein Taxan-Analogon mit prÄklinischer AktivitÄt gegen Taxan-resistenten Brustkrebs. Larotaxel (XRP9881) Übt seine zytotoxische Wirkung aus, indem es den Tubulinaufbau fÖrdert und Mikrotubuli stabilisiert, was letztendlich zum Zelltod durch Apoptose fÜhrt. Es weist die FÄhigkeit auf, die Blut-Hirn-Schranke zu Überwinden und hat eine viel geringere AffinitÄt fÜr P-Glykoprotein 1 als Docetaxel.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 156294-36-9
Sample solution is provided at 25 µL, 10mM.
Larotaxel (XRP9881) is a taxane analogue with preclinical activity against taxane-resistant breast cancer. Larotaxel (XRP9881) exerts its cytotoxic effect by promoting tubulin assembly and stabilizing microtubules, ultimately leading to cell death by apoptosis. It presents the ability to cross the blood brain barrier and has a much lower affinity for P-glycoprotein 1 than Docetaxel[1][2][3].
[1]. DiÉras V, et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann Oncol. 2008 Jul;19(7):1255-60. [2]. Morris PG, et al. Novel anti-tubulin cytotoxic agents for breast cancer. Expert Rev Anticancer Ther. 2009 Feb;9(2):175-85. [3]. Zatloukal P, et al. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J Thorac Oncol. 2008 Aug;3(8):894-901.
Average Rating: 5
(Based on Reviews and 17 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *